Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review
Background: Chronic myeloid leukemia (CML) is one of the most commonly found types of myeloproliferative neoplasms, characterized by increased proliferation of granulocytic cells without losing their differentiation ability. Imatinib, a tyrosine kinase inhibitor (TKI), can be effectively used as the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/12/11/275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850217715986333696 |
|---|---|
| author | Nurita Indarwulan Merlyna Savitri Ami Ashariati Siprianus Ugroseno Yudho Bintoro Muhammad Noor Diansyah Putu Niken Ayu Amrita Pradana Zaky Romadhon |
| author_facet | Nurita Indarwulan Merlyna Savitri Ami Ashariati Siprianus Ugroseno Yudho Bintoro Muhammad Noor Diansyah Putu Niken Ayu Amrita Pradana Zaky Romadhon |
| author_sort | Nurita Indarwulan |
| collection | DOAJ |
| description | Background: Chronic myeloid leukemia (CML) is one of the most commonly found types of myeloproliferative neoplasms, characterized by increased proliferation of granulocytic cells without losing their differentiation ability. Imatinib, a tyrosine kinase inhibitor (TKI), can be effectively used as therapy for CML. However, Imatinib can affect bone turnover thus having clinical implications on the bones of CML patients undergoing long-term Imatinib therapy. However, parameters that can accurately describe the bone condition in CML patients receiving Imatinib still need further study. A combination of imaging techniques such as bone mineral density (BMD) and bone turnover activity markers such as C-terminal telopeptide of type I collagen (CTX-1) and osteocalcin has the potential to be used as monitoring parameters for bone density abnormalities in CML patients receiving Imatinib. Objectives: This article explains the rationale for using BMD, CTX-1, and osteocalcin as monitoring parameters of bone remodeling in CML patients receiving Imatinib. Results: First, the physiological process of bone turnover will be explained. Then, we describe the role of tyrosine kinase in bone metabolism. Next, the impact of Imatinib on BMD, CTX-1, and osteocalcin will be explained. Conclusion: The assessment of bone health of CML patients on Imatinib should include both BMD tests and bone turnover marker assays such as CTX-1 and osteocalcin. |
| format | Article |
| id | doaj-art-43745d4676bb43a697dd6e367db5b715 |
| institution | OA Journals |
| issn | 2079-9721 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj-art-43745d4676bb43a697dd6e367db5b7152025-08-20T02:07:59ZengMDPI AGDiseases2079-97212024-11-01121127510.3390/diseases12110275Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical ReviewNurita Indarwulan0Merlyna Savitri1Ami Ashariati2Siprianus Ugroseno Yudho Bintoro3Muhammad Noor Diansyah4Putu Niken Ayu Amrita5Pradana Zaky Romadhon6Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, IndonesiaBackground: Chronic myeloid leukemia (CML) is one of the most commonly found types of myeloproliferative neoplasms, characterized by increased proliferation of granulocytic cells without losing their differentiation ability. Imatinib, a tyrosine kinase inhibitor (TKI), can be effectively used as therapy for CML. However, Imatinib can affect bone turnover thus having clinical implications on the bones of CML patients undergoing long-term Imatinib therapy. However, parameters that can accurately describe the bone condition in CML patients receiving Imatinib still need further study. A combination of imaging techniques such as bone mineral density (BMD) and bone turnover activity markers such as C-terminal telopeptide of type I collagen (CTX-1) and osteocalcin has the potential to be used as monitoring parameters for bone density abnormalities in CML patients receiving Imatinib. Objectives: This article explains the rationale for using BMD, CTX-1, and osteocalcin as monitoring parameters of bone remodeling in CML patients receiving Imatinib. Results: First, the physiological process of bone turnover will be explained. Then, we describe the role of tyrosine kinase in bone metabolism. Next, the impact of Imatinib on BMD, CTX-1, and osteocalcin will be explained. Conclusion: The assessment of bone health of CML patients on Imatinib should include both BMD tests and bone turnover marker assays such as CTX-1 and osteocalcin.https://www.mdpi.com/2079-9721/12/11/275chronic myeloid leukemiabone mineral densitybone turnovertyrosine kinase inhibitorCTX-1osteocalcin |
| spellingShingle | Nurita Indarwulan Merlyna Savitri Ami Ashariati Siprianus Ugroseno Yudho Bintoro Muhammad Noor Diansyah Putu Niken Ayu Amrita Pradana Zaky Romadhon Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review Diseases chronic myeloid leukemia bone mineral density bone turnover tyrosine kinase inhibitor CTX-1 osteocalcin |
| title | Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review |
| title_full | Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review |
| title_fullStr | Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review |
| title_full_unstemmed | Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review |
| title_short | Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review |
| title_sort | bone mineral density c terminal telopeptide of type i collagen and osteocalcin as monitoring parameters of bone remodeling in cml patients undergoing imatinib therapy a basic science and clinical review |
| topic | chronic myeloid leukemia bone mineral density bone turnover tyrosine kinase inhibitor CTX-1 osteocalcin |
| url | https://www.mdpi.com/2079-9721/12/11/275 |
| work_keys_str_mv | AT nuritaindarwulan bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT merlynasavitri bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT amiashariati bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT siprianusugrosenoyudhobintoro bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT muhammadnoordiansyah bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT putunikenayuamrita bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview AT pradanazakyromadhon bonemineraldensitycterminaltelopeptideoftypeicollagenandosteocalcinasmonitoringparametersofboneremodelingincmlpatientsundergoingimatinibtherapyabasicscienceandclinicalreview |